Red Light Holland Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRUFF research report →
Price Chart
About the company
Red Light Holland Corp. primarily focuses on the cultivation, manufacturing, and commercialization of magic truffles for the leisure market within the Netherlands. Additionally, the company is active in sourcing, distributing, and internationally shipping a diverse range of items, including various truffle types, cannabidiol (CBD) products, cannabis seeds, headshop merchandise, and cannabis-infused bakery items such as muffins, cookies, and cakes.
- CEO
- Todd Michael Shapiro
- IPO
- 2021
- Employees
- 104
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on TRUFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.94M
- P/E
- -2.07
- PEG
- 0.05
- P/S
- 3.00
- P/B
- 1.07
- EV/EBITDA
- -1.32
- Div Yield
- 0.00%
- Gross Margin
- 31.66%
- Op Margin
- -105.56%
- Net Margin
- -145.45%
- ROE
- -41.33%
- ROIC
- -33.45%
Latest fiscal year · YoY change
- Revenue
- $4.20M-15.1%
- Gross Profit
- $1.59M-16.8%
- Op Income
- $-4,124,766
- Net Income
- $-6,101,998-51.0%
- EPS
- $-0.01-44.6%
- OCF Growth
- -63.3%
- FCF Growth
- -27.2%
- 52W High
- $0.04
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 0.96
- RSI (14)
- 47
- Avg Volume
- 222.82K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Red Light Holland said revenue rose, gross margins stayed healthy, and the company is pivoting toward retail, fresh mushrooms, and cautious growth in emerging psychedelic markets.· March 1, 2024
- Quarter revenue was $1.3 million, up 9.9% year over year; nine-month revenue was $3.5 million, up 28.9%.
- Gross profit margins remained strong at 42.3% for the quarter and 43.6% year to date, though management said mix and pricing pressured margins a bit.
- Management said the business is shifting away from DTC/Amazon toward B2B and retail channels, where it sees better economics and more control.
- Happy Caps distribution increased, but there were questions about Amazon reviews, sold-out SKUs, and product labeling/instructions.
- The Peterborough farm build remains a major future catalyst, with management saying it is still on track and could support much higher revenue once ramped.
For the quarter ended December 31, revenue was $1.3 million, up 9.9% from the same period last year. For the nine months ended December 31, revenue was $3.5 million, up 28.9% year over year. Gross profit margin was 42.3% for the quarter and 43.6% on a year-to-date basis. Management did not provide EPS in the call. On guidance, the company said Amazon is a slower season and that all SKUs should be back in the coming weeks, but it is shifting emphasis toward retail/B2B channels. On the farm build, management reiterated prior expectations that the project could ultimately support about 80,000 per week and roughly $16 million to $17 million in revenue, with ramp-up stages along the way.
Todd Shapiro struck an upbeat but defensive tone, repeatedly emphasizing transparency, shareholder engagement, and cautious long-term growth. Strategically, he said the company is building around brand development, distribution gains, and a shift toward business-to-business and retail rather than relying mainly on direct-to-consumer sales. He also said Red Light wants to avoid the mistakes of cannabis companies that overbuilt too early, preferring to wait for the right market and regulatory conditions before moving aggressively into psychedelics.
David Ascott focused on the hard numbers and framed the quarter as evidence that revenue growth is outpacing overhead growth. He cited $1.3 million in quarterly revenue, $3.5 million in nine-month revenue, and gross margins of 42.3% and 43.6%, saying the company is maintaining healthy profitability on gross profit despite seasonality and product-mix swings. He said the growth in revenue and gross margin has outpaced G&A movement and that the company is working to right-size costs across North America and Europe.
The most notable questions centered on the drop in gross profit despite higher revenue, Amazon reviews and alleged mislabeled Happy Caps boxes, retailer listings that may no longer be active, the strategy for SR Wholesale, the Peterborough farm build, and possible share buybacks. Management said the gross margin softness mainly reflected product mix, seasonality, and some pricing pressure from competitive conditions, especially in Happy Caps and Amazon. On the farm, management said the build is being timed carefully to save money, with orders and construction staged over time, and on buybacks Todd said approximately 1.5 million shares have already been repurchased under the normal course issuer bid and that future repurchases will depend on cash and the quarterly budget.
The bullish case from this call is that revenue is growing, gross margins are still solid, and management believes it is improving the cost structure while scaling. The company also described meaningful distribution gains in Happy Caps, progress toward larger retail contracts, a potentially important Peterborough farm catalyst, and optionality in psilocybin and related adjacent markets.
The bear case is that gross margin softness, Amazon friction, and consumer-review complaints suggest scaling pains and weaker economics in parts of the business. Management also acknowledged a burn, a difficult economy, long sales cycles, and regulatory uncertainty around emerging psychedelic markets, while the stock-price discussion and defensive Q&A tone highlighted ongoing investor concerns.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.9%
- Shares Outstanding
- 419.54M
- Float Shares
- 381.15M
Our TRUFF coverage
Recent articles, reports, and earnings notes.
No research on TRUFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRUFF report →Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
newsfilecorp.com · Aug 20
Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO
newsfilecorp.com · Aug 19
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
newsfilecorp.com · Aug 14
Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE
newsfilecorp.com · Aug 4
Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
newsfilecorp.com · Jul 29
Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp
newsfilecorp.com · Jul 17
Red Light Holland Announces New Filament Health PEX010 European Research Shipment
newsfilecorp.com · Jul 16
Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg
newsfilecorp.com · Jul 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.